CBX6

Across TCGA pan-cancer cohorts, CBX6 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CBX6 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CBX6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CBX6 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LUSC, ESCA, and LIHC are the cancer types where CBX6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.003	0.819	<.001	12	view →
ESCA	OS	Median	All	0.022	0.681	<.001	9	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
BLCA	DFS	Median	III,IV	1.000	0.538	.025	7	view →
SKCM	DFS	Median	II,III,IV	0.192	0.707	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CBX6–LUSC (OS)

Open the LUSC breakdown →